SG11202106898VA - M2-defective poxvirus - Google Patents

M2-defective poxvirus

Info

Publication number
SG11202106898VA
SG11202106898VA SG11202106898VA SG11202106898VA SG11202106898VA SG 11202106898V A SG11202106898V A SG 11202106898VA SG 11202106898V A SG11202106898V A SG 11202106898VA SG 11202106898V A SG11202106898V A SG 11202106898VA SG 11202106898V A SG11202106898V A SG 11202106898VA
Authority
SG
Singapore
Prior art keywords
defective poxvirus
poxvirus
defective
Prior art date
Application number
SG11202106898VA
Inventor
Patricia Kleinpeter
Jean-Baptiste Marchand
Christelle Remy
Doris Schmitt
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of SG11202106898VA publication Critical patent/SG11202106898VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
SG11202106898VA 2018-12-28 2019-12-27 M2-defective poxvirus SG11202106898VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306874 2018-12-28
EP19306022 2019-08-21
PCT/EP2019/087063 WO2020136235A1 (en) 2018-12-28 2019-12-27 M2-defective poxvirus

Publications (1)

Publication Number Publication Date
SG11202106898VA true SG11202106898VA (en) 2021-07-29

Family

ID=69005733

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106898VA SG11202106898VA (en) 2018-12-28 2019-12-27 M2-defective poxvirus

Country Status (12)

Country Link
US (1) US20220056481A1 (en)
EP (1) EP3902562A1 (en)
JP (1) JP2022515823A (en)
KR (1) KR20210110838A (en)
CN (1) CN113453712A (en)
AU (1) AU2019412516A1 (en)
BR (1) BR112021012630A2 (en)
CA (1) CA3124773A1 (en)
IL (1) IL284421A (en)
MX (1) MX2021007860A (en)
SG (1) SG11202106898VA (en)
WO (1) WO2020136235A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
CN117756949B (en) * 2024-02-21 2024-10-15 中国人民解放军军事科学院军事医学研究院 Orthopoxvirus fusion antigen and application thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
FR2672895B1 (en) * 1991-02-15 1995-05-12 Transgene Sa PROCESS FOR THE PURIFICATION OF A HIGHLY GLYCOSYLATED PROTEIN.
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
CA2153336C (en) * 1993-01-21 2006-12-12 Enzo Paoletti Recombinant virus immunotherapy
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
EP0805854A4 (en) * 1995-01-13 2000-06-07 Virogenetics Corp Immunogenic compositions containing recombinant attenuated poxviruses expressing htlv antigens
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
FR2766091A1 (en) 1997-07-18 1999-01-22 Transgene Sa ANTITUMOR COMPOSITION BASED ON MODIFIED IMMUNOGENIC POLYPEPTIDE WITH CELL LOCATION
TR200200735T2 (en) 1998-12-23 2002-06-21 Pfizer Inc. Human monoclonal antibodies for CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
FR2790955B1 (en) 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris USE OF STABILIZED OLIGONUCLEOTIDES AS ANTI-TUMOR ACTIVE INGREDIENT
US6322980B1 (en) 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
MXPA02001911A (en) 1999-08-24 2003-07-21 Medarex Inc Human ctla 4 antibodies and their uses.
US6399385B1 (en) 1999-09-29 2002-06-04 The Trustees Of The University Of Pennsylvania Methods for rapid PEG-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
EP1366167A2 (en) * 2001-01-26 2003-12-03 Transgene S.A. Biological organism for preparing pharmaceutical compositions for treating mammals
NZ533302A (en) 2001-12-10 2005-11-25 Bavarian Nordic As Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions containing a disaaccharide and a pharmaceutically acceptable polymer i.e. dextran or polyvinylpyrrolidon (PVP)
AU2004263813B8 (en) 2003-02-25 2008-09-11 Medimmune, Llc Methods of producing influenza vaccine compositions
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
GB0502661D0 (en) 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
US20060205080A1 (en) 2005-03-01 2006-09-14 David Frey Formulations for therapeutic viruses having enhanced storage stability
FR2884255B1 (en) 2005-04-11 2010-11-05 Vivalis USE OF EBX AVIATION STEM CELL LINES FOR THE PRODUCTION OF INFLUENZA VACCINE
DE102005032974B4 (en) 2005-07-14 2013-11-07 Siemens Aktiengesellschaft Method for 3D visualization of vascular inserts in the human body with the C-arm
KR101357685B1 (en) 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 Stabilizing formulations for recombinant viruses
EP2013348A4 (en) 2006-03-30 2009-09-02 Univ California Methods and compositions for localized secretion of anti-ctla-4 antibodies
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
MX348525B (en) 2006-06-20 2017-06-16 Transgene Sa Process for producing poxviruses and poxvirus compositions.
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
CA2676149C (en) 2007-05-14 2016-06-21 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
PT103865A (en) 2007-10-25 2009-05-15 Univ De Coimbra NANO-LIPID BASIC CONVEYORS FOR DIRECT DELIVERY OF VIRAL VECTORS AND PROCESS FOR THEIR PRODUCTION
NZ584199A (en) * 2007-11-19 2012-07-27 Transgene Sa Poxviral oncolytic vectors comprising a defective 14l and/or f4l gene
CN101868546B (en) 2007-11-19 2013-06-05 特朗斯吉有限公司 Poxviral oncolytic vectors
MX2010008970A (en) 2008-02-12 2011-05-30 Sanofi Pasteur Ltd Methods using ion exchange and gel filtration chromatography for poxvirus purification.
KR20240093808A (en) 2008-12-09 2024-06-24 제넨테크, 인크. Anti-pd-l1 antibodies and their use to enhance t-cell function
BRPI1007743A2 (en) 2009-05-12 2017-09-19 Transgene Sa IMMORTALIZED AVIAN CELL LINEAGES, USES OF AN IMMORTALIZED AVIAN CELL LINEAGE, METHODS FOR VIRUS PRODUCTION AND METHODS FOR PROTEIN PRODUCTION
PL2504364T3 (en) 2009-11-24 2017-12-29 Medimmune Limited Targeted binding agents against b7-h1
ES2699965T3 (en) 2011-03-10 2019-02-13 Provectus Pharmatech Inc A combination of rose bengal and anti-CTLA4 antibody for use in the treatment of cancer
AU2012294606B2 (en) 2011-08-05 2016-10-06 Sillajen Biotherapeutics, Inc. Methods and compositions for production of vaccinia virus
JP6138813B2 (en) 2011-11-28 2017-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Anti-PD-L1 antibody and use thereof
CN113967253A (en) 2012-05-15 2022-01-25 百时美施贵宝公司 Immunotherapy by disrupting PD-1/PD-L1 signaling
CN109467601B (en) 2012-05-31 2022-07-08 索伦托药业有限公司 Antigen binding proteins that bind to PD-L1
TWI690322B (en) 2012-10-02 2020-04-11 法商傳斯堅公司 Virus-containing formulation and use thereof
KR102457060B1 (en) * 2014-04-10 2022-10-19 트랜스진 Poxviral oncolytic vectors
HUE045108T2 (en) * 2014-07-16 2019-12-30 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
CN107206063B (en) 2014-12-01 2021-09-28 特兰斯吉恩股份有限公司 Stable liquid vaccinia virus formulations
CA2978942A1 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
KR20230028478A (en) 2015-05-29 2023-02-28 아게누스 인코포레이티드 Anti-ctla-4 antibodies and methods of use thereof
WO2018089293A2 (en) * 2016-11-08 2018-05-17 Qilu Puget Sound Biotherapeutics Corporation Anti-pd1 and anti-ctla4 antibodies
WO2018091680A1 (en) * 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
KR20190097240A (en) 2016-12-28 2019-08-20 트랜스진 에스.에이. Oncolytic viruses and therapeutic molecules

Also Published As

Publication number Publication date
US20220056481A1 (en) 2022-02-24
IL284421A (en) 2021-08-31
JP2022515823A (en) 2022-02-22
MX2021007860A (en) 2021-10-26
EP3902562A1 (en) 2021-11-03
CA3124773A1 (en) 2020-07-02
KR20210110838A (en) 2021-09-09
AU2019412516A1 (en) 2021-07-15
CN113453712A (en) 2021-09-28
BR112021012630A2 (en) 2022-12-13
WO2020136235A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
DK3793565T3 (en) Mcl-1-inhibitorer
DK3467457T3 (en) Vibrationssensor
DK3759096T3 (en) Cd73-inhibitorer
CA185383S (en) Casque
CA185384S (en) Casque
CA185382S (en) Casque
CA185385S (en) Casque
DK3773537T3 (en) Stat3-hæmmere
DK3554057T3 (en) Audioheadsetsystem
DK3768830T3 (en) Cancerterapi
DK3613739T3 (en) Integrin-antagonister
DK3753395T3 (en) Indvendigt luftstyringssystem
CA184989S (en) Uroflowmeter
DK3633783T3 (en) Universal-powerbank
CA184994S (en) Uroflowmeter
IL284421A (en) M2-defective poxvirus
EP3841303C0 (en) Microblower
DK3768906T3 (en) Træmodul
DK3674425T3 (en) Stålwire
DK3650069T3 (en) Trakeostomiventil
DK3578923T3 (en) Navigationssystem
GB201805799D0 (en) b
DK3570498T3 (en) Adaptivt hvac-styresystem
CA187782S (en) Pompon-maker
DK3542617T3 (en) Etikette